Targeted agents in treatment of neuroendocrine tumors of pancreas

Journal of the Pancreas

Volumn 15, Issue 4, 2014, Pages 351-353

  Karampelas, Ilias N ^a   Syrigos, Kostas N ^b   Saif, Muhammad Wasif ^c  

^a Athens Medical Society   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Diabetes; Hyperinsulinemia; Pancreatic cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; EVEROLIMUS; GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; SUNITINIB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN;

ARTICLE; DISEASE CONTROL; HUMAN; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; ANALOGS AND DERIVATIVES; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROCEDURES; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; SIROLIMUS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905167396     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: 10.6092/1590-8577%2F2694     Document Type: Article

References (13)

1. KjellÖberg, Daniel Castellano. Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer and Metastasis Reviews, March 2011, Volume 30, Issue 1 Supplement, 3-7
2. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19: 1727-1733.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26:3063-3072. [PMID:18565894]
4. Shah MH, Ito T, Lombard-Bohas C, Wolin EM, Van Cutsem E, Sachs C, Winkler RE, et al. Everolimus in patients with advanced pancreatic neuroendocrine tumors: Updated results of a randomized, doubleblind, placebo-controlled multicenter phase III trial (RADIANT-3). J Clin Oncol. 2011; 29(Suppl. 4):158.
5. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999; 17(2):600. [PMID:10080605]
6. Raymond E, Dahan L, Raoul J-L, Bang YJ, Borbath I, Lombard- Bohas C, Valle J, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-13.
7. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27(28):4656. [PMID:19704057]
8. Arnold R, Wittenberg M, Rinke A, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al. Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. ASCO 2013 Abstract No: # 4030.
9. Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, et al. Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group. ASCO 2013 Abstract No: #4136.
10. Bajetta E, Catena L, Pusceddu S, Spada F, Fazio N, Blanco G, Ricci S, et al. Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment. J Clin Oncol. 32, 2014 (suppl; abstr#e15160).
11. Geboes KP, Laurent S, Verroken C, Cesmeli E, Lambert B, Smeets P, Vanlander A, et al. Durable disease control with sunitinib and everolimus in well-differentiated neuroendocrine tumors of the pancreas with a high ki67 index. J Clin Oncol. 32, 2014 (suppl; abstr#e15161).
12. Kulke MH. Systemic therapy for advanced pancreatic neuroendocrine tumors. Semin Oncol. 2013; 40(1): 75-83. [PMID:23391115]
13. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8: 299-309. [PMID:16226705]